Middle East & Africa Point-of-Care Diagnostics Market by Product Type, End-Use, and Country-wise Insights: Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031

Description

Persistence Market Research has recently published an in-depth report on the Point-of-Care (POC) Diagnostics market in the Middle East and Africa (MEA). This comprehensive study evaluates key market dynamics, including the driving factors, emerging trends, challenges, and opportunities, providing a detailed analysis of the market structure. The report highlights critical data and projections regarding the expected growth of the MEA Point-of-Care Diagnostics market from 2024 to 2031.

Key Insights:

MEA Point-of-Care Diagnostics Market Size (2024E): US$ 2.7 Bn
Projected Market Value (2031F): US$ 6.1 Bn
Market Growth Rate (CAGR 2024 to 2031): 12.3%

Report Scope:

Point-of-care diagnostics (POC) refers to medical diagnostic testing conducted at or near the site of patient care. This innovative approach enables quick and efficient diagnostics, providing real-time results and helping clinicians make immediate treatment decisions. The market growth in the MEA region is driven by increasing healthcare access, a growing demand for fast and accurate diagnostics, and the adoption of advanced technologies such as biosensors and microfluidics.

Market Growth Drivers:

The MEA Point-of-Care Diagnostics market is driven by several key factors, including the rising prevalence of chronic diseases, increasing healthcare awareness, and improvements in healthcare infrastructure across the region. The demand for quick diagnostic solutions in rural and remote areas, coupled with the need for timely treatment, is propelling the adoption of point-of-care diagnostics. Additionally, the growing use of home-based diagnostics, which offers convenience and accessibility, is significantly contributing to the market's expansion. Technological innovations, such as the development of portable and user-friendly diagnostic devices, are further enhancing the market potential. The COVID-19 pandemic has also accelerated the adoption of point-of-care testing, with increased demand for rapid testing solutions in both healthcare settings and at home.

Market Restraints:

Despite the promising growth prospects, the MEA Point-of-Care Diagnostics market faces several challenges. One of the primary concerns is the high cost of advanced diagnostic devices, which can be prohibitive for healthcare facilities in low-income regions. Additionally, the lack of adequate trained personnel to operate point-of-care diagnostic devices and the uneven distribution of healthcare resources in some parts of the region are restraining market growth. Furthermore, regulatory hurdles and the slow pace of adoption in certain countries may hinder the widespread implementation of point-of-care testing solutions.

Market Opportunities:

The MEA Point-of-Care Diagnostics market presents significant growth opportunities driven by technological advancements, increasing healthcare investments, and a shift toward personalized medicine. Innovations in mobile health (mHealth) and telemedicine are creating new avenues for POC testing, allowing remote patient monitoring and diagnostics. The expansion of healthcare networks and the increasing number of diagnostic centers are also contributing to the market's growth. Additionally, government initiatives aimed at improving healthcare access in underserved areas present lucrative opportunities for market players to capitalize on.

Key Questions Answered in the Report:

What are the primary factors driving the growth of the point-of-care diagnostics market in the Middle East and Africa?
How is the demand for rapid and accurate diagnostics influencing market trends in the region?
What challenges are faced by healthcare providers in adopting point-of-care diagnostic technologies, and how are they being addressed?
What role does technology, such as mobile health and telemedicine, play in the expansion of point-of-care diagnostics in MEA?
Which countries in the MEA region are showing the most growth potential for point-of-care diagnostics, and why?

Competitive Intelligence and Business Strategy:

Leading players in the MEA Point-of-Care Diagnostics Market, including Abbott Laboratories, Roche Diagnostics, and Siemens Healthineers, are focusing on technological innovations, strategic partnerships, and regional expansion to strengthen their market position. These companies are investing in research and development to introduce more affordable, accurate, and efficient diagnostic solutions tailored to the specific needs of the MEA region. Furthermore, collaborations with local healthcare providers, government bodies, and NGOs are essential for expanding the market footprint and improving healthcare delivery in underserved regions.

Key Companies Profiled:

QIAGEN
Danaher Corporation
F. Hoffmann-La Roche Ltd
BD (Becton Dickinson)
Abbott
BIOMERIEUX
Nova Biomedical
Werfen
Trividia Health, Inc.
Siemens Healthcare Private Limited

Middle East and Africa Point-of-Care Diagnostics Market Segmentation

By Product

Infectious Disease
Glucose Monitoring
Hepatitis C
HIV Testing
Sexually Transmitted Disease (STD)
Influenza
Respiratory Infection
Tropical Disease
Healthcare-Associated Infection (HAI)
Pregnancy and Fertility
Tumor/Cancer Marker
Cardiometabolic
Cholesterol
Coagulation
Hematology
Urinalysis

By Prescription Mode

Prescription-based
OTC

By Type

Consumables and Kits
Software and Services
Devices
Accessories

By End User

Hospitals
Ambulatory Care Settings
Home Care
Research Laboratories

By Country

Kingdom of Saudi Arabia
United Arab Emirates
South Africa
Rest of Gulf Cooperation Council
Rest of the Middle East and Africa

Product Code: PMRREP34917

1. Executive Summary

1.1. Middle East & Africa Point-of-Care Diagnostics Market Snapshot, 2024 and 2031
1.2. Market Opportunity Assessment, 2024 - 2031, US$ Bn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations

2. Market Overview

2.1. Market Scope and Definition
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Opportunity
- 2.2.4. Challenges
- 2.2.5. Key Trends
2.3. Macro-Economic Factors
- 2.3.1. Middle East & Africa Sectorial Outlook
- 2.3.2. Middle East & Africa GDP Growth Outlook
- 2.3.3. Middle East & Africa Healthcare Spending Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

3.1. Product Adoption Analysis
3.2. Epidemiology - Infectious Diseases and Chronic Conditions
3.3. Technology Assessment
3.4. Regulatory Landscape
3.5. Value Chain Analysis
3.6. Key Deals and Mergers
3.7. PESTLE Analysis
3.8. Porter's Five Force Analysis

4. Price Trend Analysis, 2019 - 2031

4.1. Key Highlights
4.2. Key Factors Impacting Product Prices
4.3. Pricing Analysis, By Product
4.4. Regional Prices and Preferences

5. Middle East & Africa Point-of-Care Diagnostics Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

5.1. Key Highlights
- 5.1.1. Market Volume (Units) Projections
- 5.1.2. Market Size (US$ Bn) and Y-o-Y Growth
- 5.1.3. Absolute $ Opportunity
5.2. Market Size (US$ Bn) Analysis and Forecast
- 5.2.1. Historical Market Size (US$ Bn) Analysis, 2019 - 2023
- 5.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2023-2031
5.3. Middle East & Africa Point-of-Care Diagnostics Market Outlook: Product
- 5.3.1. Introduction / Key Findings
- 5.3.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Product, 2019 - 2023
- 5.3.3. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Product, 2024 - 2031
  - 5.3.3.1. Infectious Disease
  - 5.3.3.2. Glucose Monitoring
  - 5.3.3.3. Hepatitis C
  - 5.3.3.4. HIV
  - 5.3.3.5. Sexually Transmitted Disease (STD)
  - 5.3.3.6. Influenza
  - 5.3.3.7. Tropical Disease
  - 5.3.3.8. Healthcare-Associated Infection (HAI)
  - 5.3.3.9. Pregnancy and Fertility
  - 5.3.3.10. Respiratory Infection
  - 5.3.3.11. Other Infectious Disease
  - 5.3.3.12. Tumor/Cancer Marker
  - 5.3.3.13. Cardiometabolic
  - 5.3.3.14. Cholesterol
  - 5.3.3.15. Coagulation
  - 5.3.3.16. Hematology
  - 5.3.3.17. Urinalysis
5.4. Market Attractiveness Analysis: Product
5.5. Middle East & Africa Point-of-Care Diagnostics Market Outlook: Prescription Mode
- 5.5.1. Introduction / Key Findings
- 5.5.2. Historical Market Size (US$ Bn) Analysis, By Prescription Mode, 2019 - 2023
- 5.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Prescription Mode, 2024 - 2031
  - 5.5.3.1. Prescription-based
  - 5.5.3.2. OTC
5.6. Market Attractiveness Analysis: Prescription Mode
5.7. Middle East & Africa Point-of-Care Diagnostics Market Outlook: Type
- 5.7.1. Introduction / Key Findings
- 5.7.2. Historical Market Size (US$ Bn) Analysis, By Type, 2019 - 2023
- 5.7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024 - 2031
  - 5.7.3.1. Consumables and Kits
  - 5.7.3.2. Software and Services
  - 5.7.3.3. Devices
  - 5.7.3.4. Accessories
5.8. Market Attractiveness Analysis: Type
5.9. Middle East & Africa Point-of-Care Diagnostics Market Outlook: End User
- 5.9.1. Introduction / Key Findings
- 5.9.2. Historical Market Size (US$ Bn) Analysis, By End User, 2019 - 2023
- 5.9.3. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
  - 5.9.3.1. Hospitals
  - 5.9.3.2. Ambulatory Care Settings
  - 5.9.3.3. Home Care
  - 5.9.3.4. Research Laboratories
  - 5.9.3.5. Others
5.10. Market Attractiveness Analysis: End User

6. Middle East & Africa Point-of-Care Diagnostics Market Outlook: Country

6.1. Key Highlights
6.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Country, 2019 - 2023
6.3. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Country, 2024 - 2031
- 6.3.1. Kingdom of Saudi Arabia
- 6.3.2. United Arab Emirates
- 6.3.3. South Africa
- 6.3.4. Rest of GCC
- 6.3.5. Rest of Middle East & Africa
6.4. Market Attractiveness Analysis: Country

7. Kingdom of Saudi Arabia Filtered Hearing Protection Devices Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

7.1. Key Highlights
7.2. Pricing Analysis
7.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Market, 2019 - 2023
- 7.3.1. By Product
- 7.3.2. By Prescription Mode
- 7.3.3. By Type
- 7.3.4. By End User
7.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Product, 2024 - 2031
- 7.4.1. Infectious Disease
- 7.4.2. Glucose Monitoring
- 7.4.3. Hepatitis C
- 7.4.4. HIV
- 7.4.5. Sexually Transmitted Disease (STD)
- 7.4.6. Influenza
- 7.4.7. Respiratory Infection
- 7.4.8. Tropical Disease
- 7.4.9. Healthcare-Associated Infection (HAI)
- 7.4.10. Pregnancy and Fertility
- 7.4.11. Tumor/Cancer Marker
- 7.4.12. Cardiometabolic
- 7.4.13. Cholesterol
- 7.4.14. Coagulation
- 7.4.15. Hematology
- 7.4.16. Urinalysis
7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Prescription Mode, 2024 - 2031
- 7.5.1. Prescription-Based
- 7.5.2. OTC
7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024 - 2031
- 7.6.1. Consumables and Kits
- 7.6.2. Software and Services
- 7.6.3. Devices
- 7.6.4. Accessories
7.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
- 7.7.1. Hospitals
- 7.7.2. Ambulatory Care Settings
- 7.7.3. Home Care
- 7.7.4. Research Laboratories
- 7.7.5. Others
7.8. Market Attractiveness Analysis

8. United Arab Emirates Filtered Hearing Protection Devices Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

8.1. Key Highlights
8.2. Pricing Analysis
8.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Market, 2019 - 2023
- 8.3.1. By Product
- 8.3.2. By Prescription Mode
- 8.3.3. By Type
- 8.3.4. By End User
8.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Product, 2024 - 2031
- 8.4.1. Infectious Disease
- 8.4.2. Glucose Monitoring Products
- 8.4.3. Hepatitis C
- 8.4.4. HIV
- 8.4.5. Sexually Transmitted Disease (STD)
- 8.4.6. Influenza
- 8.4.7. Respiratory Infection
- 8.4.8. Tropical Disease
- 8.4.9. Healthcare-Associated Infection (HAI)
- 8.4.10. Pregnancy and Fertility
- 8.4.11. Tumor/Cancer Marker
- 8.4.12. Cardiometabolic
- 8.4.13. Cholesterol
- 8.4.14. Coagulation
- 8.4.15. Hematology
- 8.4.16. Urinalysis
8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Prescription Mode, 2024 - 2031
- 8.5.1. Prescription-Based
- 8.5.2. OTC
8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024 - 2031
- 8.6.1. Consumables and Kits
- 8.6.2. Software and Services
- 8.6.3. Devices
- 8.6.4. Accessories
8.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
- 8.7.1. Hospitals
- 8.7.2. Ambulatory Care Settings
- 8.7.3. Home Care
- 8.7.4. Research Laboratories
- 8.7.5. Others
8.8. Market Attractiveness Analysis

9. Rest of GCC Filtered Hearing Protection Devices Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

9.1. Key Highlights
9.2. Pricing Analysis
9.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Market, 2019 - 2023
- 9.3.1. By Product
- 9.3.2. By Prescription Mode
- 9.3.3. By Type
- 9.3.4. By End User
9.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Product, 2024 - 2031
- 9.4.1. Infectious Disease
- 9.4.2. Glucose Monitoring Products
- 9.4.3. Hepatitis C
- 9.4.4. HIV
- 9.4.5. Sexually Transmitted Disease (STD)
- 9.4.6. Influenza
- 9.4.7. Respiratory Infection
- 9.4.8. Tropical Disease
- 9.4.9. Healthcare-Associated Infection (HAI)
- 9.4.10. Pregnancy and Fertility
- 9.4.11. Tumor/Cancer Marker
- 9.4.12. Cardiometabolic
- 9.4.13. Cholesterol
- 9.4.14. Coagulation
- 9.4.15. Hematology
- 9.4.16. Urinalysis
9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Prescription Mode, 2024 - 2031
- 9.5.1. Prescription-Based
- 9.5.2. OTC
9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024 - 2031
- 9.6.1. Consumables and Kits
- 9.6.2. Software and Services
- 9.6.3. Devices
- 9.6.4. Accessories
9.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
- 9.7.1. Hospitals
- 9.7.2. Ambulatory Care Settings
- 9.7.3. Home Care
- 9.7.4. Research Laboratories
- 9.7.5. Others
9.8. Market Attractiveness Analysis

10. Rest of Middle East & Africa Filtered Hearing Protection Devices Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

10.1. Key Highlights
10.2. Pricing Analysis
10.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Market, 2019 - 2023
- 10.3.1. By Product
- 10.3.2. By Prescription Mode
- 10.3.3. By Type
- 10.3.4. By End User
10.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Product, 2024 - 2031
- 10.4.1. Infectious Disease
- 10.4.2. Glucose Monitoring Products
- 10.4.3. Hepatitis C
- 10.4.4. HIV
- 10.4.5. Sexually Transmitted Disease (STD)
- 10.4.6. Influenza
- 10.4.7. Respiratory Infection
- 10.4.8. Tropical Disease
- 10.4.9. Healthcare-Associated Infection (HAI)
- 10.4.10. Pregnancy and Fertility
- 10.4.11. Tumor/Cancer Marker
- 10.4.12. Cardiometabolic
- 10.4.13. Cholesterol
- 10.4.14. Coagulation
- 10.4.15. Hematology
- 10.4.16. Urinalysis
10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Prescription Mode, 2024 - 2031
- 10.5.1. Prescription-based
- 10.5.2. OTC
10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024 - 2031
- 10.6.1. Consumables and Kits
- 10.6.2. Software and Services
- 10.6.3. Devices
- 10.6.4. Accessories
10.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
- 10.7.1. Hospitals
- 10.7.2. Ambulatory Care Settings
- 10.7.3. Home Care
- 10.7.4. Research Laboratories
- 10.7.5. Others
10.8. Market Attractiveness Analysis

11. Competition Landscape

11.1. Market Share Analysis, 2023
11.2. Market Structure
- 11.2.1. Competition Intensity Mapping by Market
- 11.2.2. Competition Dashboard
11.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
- 11.3.1. QIAGEN
  - 11.3.1.1. Overview
  - 11.3.1.2. Segments and Products
  - 11.3.1.3. Key Financials
  - 11.3.1.4. Market Developments
  - 11.3.1.5. Market Strategy
- 11.3.2. Danaher Corporation
- 11.3.3. F. Hoffmann-La Roche Ltd
- 11.3.4. BD (Becton Dickinson)
- 11.3.5. Abbott
- 11.3.6. BIOMERIEUX
- 11.3.7. Nova Biomedical
- 11.3.8. Werfen
- 11.3.9. Trividia Health, Inc.
- 11.3.10. Siemens Healthcare Private Limited

12. Appendix

12.1. Research Methodology
12.2. Research Assumptions
12.3. Acronyms and Abbreviations